Letrozole significantly improves growth potential in a pubertal boy with growth hormone deficiency

Pediatrics

Volumn 115, Issue 2, 2005, Pages

  Zhou, Ping ^a   Shah, Bina ^a   Prasad, Kris ^a   David, Raphael ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aromatase inhibitor; Bone mineral density; Growth hormone; Hormonal control; Short stature

Indexed keywords

AROMATASE INHIBITOR; CALCIUM; ERGOCALCIFEROL; GROWTH HORMONE; LETROZOLE; BIOLOGICAL MARKER; HUMAN GROWTH HORMONE; LIPID; NITRILE; SOMATOMEDIN C; TESTOSTERONE; TRIAZOLE DERIVATIVE;

ADOLESCENT; ANAMNESIS; ARTICLE; BODY GROWTH; BODY MASS; CASE REPORT; CHILD GROWTH; CLINICAL EXAMINATION; CLINICAL FEATURE; ESTROGEN SYNTHESIS; GROWTH HORMONE DEFICIENCY; HUMAN; LABORATORY TEST; MALE; PRIORITY JOURNAL; PUBERTY; TREATMENT OUTCOME; BLOOD; BONE DENSITY; DRUG COMBINATION; GROWTH DISORDER;

ADOLESCENT; AROMATASE INHIBITORS; BIOLOGICAL MARKERS; BONE DENSITY; DRUG THERAPY, COMBINATION; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; MALE; NITRILES; TESTOSTERONE; TRIAZOLES;

EID: 17844393677     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-1536     Document Type: Article

References (18)

1. Grumbach M, Auchus RJ. Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab. 1999;84:4677-4694
2. Meinhardt U, Mullis PE. The aromatase cytochrome P-450 and its clinical impact. Horm Res. 2002;57:145-152
3. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331:1056-1061
4. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80:3689-3698
5. Mauras N, O'Brien KO, Oerter Klein K, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab. 2000;85:2370-2377
6. Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet. 2001;357:1743-1748
7. Wickman S, Kajantie E, Dunkel L. Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys. J Clin Endocrinol Metab. 2003;88:3785-3793
8. Wickman S, Saukkonen T, Dunkel L. The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. Eur J Endocrinol. 2002;146:339-346
9. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952;40:423-441
10. Stevens DA, Williams GR. Hormone regulation of chondrocyte differentiation and endochondral bone formation. Mol Cell Endocrinol. 1999;151:195-204
11. Orwoll ES. Androgens as anabolic agents for bone. Trends Endocrinol Metab. 1996;7:77-84
12. Wiren K, Keenan E, Zhang X, Ramsey B, Orwoll E. Homologous androgen receptor up-regulation in osteoblastic cells may be associated with enhanced functional androgen responsiveness. Endocrinology. 1999;140:3114-3124
13. Vanderschueren D. Androgens and their role in skeletal homeostasis. Horm Res. 1996;46:95-98
14. Lanes R, Gunczler P. Final height after combined growth hormone and gonadotrophin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Clin Endocrinol (Oxf). 1998;49:197-202
15. Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab. 1999;84:4480-4488
16. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999;84:4583-4590
17. Boot AM, De Muinck Keizer-Schrama S, Pols HA, Krenning EP, Drop SL. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J Clin Endocrinol Metab. 1998;83:370-373
18. Yanovski JA, Rose SR, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med. 2003;348:908-917